Advancing de novo lipogenesis: Genetic and metabolic insights

Sean M Hartig; Mark A Herman

doi:10.1016/j.cmet.2024.12.001

Advancing de novo lipogenesis: Genetic and metabolic insights

Cell Metab. 2025 Jan 7;37(1):3-4. doi: 10.1016/j.cmet.2024.12.001.

Authors

Sean M Hartig¹, Mark A Herman²

Affiliations

¹ Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
² Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: [email protected].

PMID: 39778518
DOI: 10.1016/j.cmet.2024.12.001

Abstract

De novo lipogenesis (DNL) is the process whereby cells synthesize fatty acids from acetyl-CoA, contributing to steatosis in fatty liver disease. Two new studies, using genetic mouse models, metabolomics, and pharmacology, identified alternative pathways in DNL and unexpected physiological effects when targeting key enzymes in this pathway.

MeSH terms

Acetyl Coenzyme A / metabolism
Animals
Fatty Acids / metabolism
Fatty Liver / genetics
Fatty Liver / metabolism
Humans
Lipogenesis* / genetics
Mice

Substances

Acetyl Coenzyme A
Fatty Acids